

## MINDACT, validating a new prognostic tool



The trial enrolled  
**6,693**  
early-stage breast cancer patients



**112**  
cancer centres  
and hospitals



**9**  
countries



**47**  
million €  
to fund the trial



- ✓ De-escalation of therapies
- ✓ Pioneering precision medicine
- ✓ Better and personalised treatment
- ✓ Potential savings for society
- ✓ Goldmine for future research



**70-gene**  
prognosis signature

can help with decision-making  
about giving  
chemotherapy or not

## Patient categories


Clinical &  
genomic tests  
indicate  
low risk  
of recurrence



Clinical &  
genomic tests  
indicate  
high risk  
of recurrence



Clinical &  
genomic tests  
are discordant



RANDOMISATION



# 46%

of patients  
could be spared  
unnecessary  
chemotherapy

Highest scientific  
evidence  
**level 1A**

